---
title: "RBC Capital Remains a Hold on Apellis Pharmaceuticals (APLS)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285944432.md"
description: "RBC Capital's Lisa Walter has maintained a Hold rating on Apellis Pharmaceuticals (APLS) with a price target of $41.00, slightly below the current share price of $41.03. Walter, a 3-star analyst, has an average return of 2.6% and a 52.63% success rate. The consensus among analysts for Apellis is also a Hold, with an average price target of $39.59."
datetime: "2026-05-11T12:41:55.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285944432.md)
  - [en](https://longbridge.com/en/news/285944432.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285944432.md)
---

# RBC Capital Remains a Hold on Apellis Pharmaceuticals (APLS)

In a report released on May 8, Lisa Walter from RBC Capital reiterated a Hold rating on Apellis Pharmaceuticals, with a price target of $41.00. The company’s shares closed last Friday at $41.03.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

According to TipRanks, Walter is a 3-star analyst with an average return of 2.6% and a 52.63% success rate. Walter covers the Healthcare sector, focusing on stocks such as Rhythm Pharmaceuticals, United Therapeutics, and Apellis Pharmaceuticals.

Currently, the analyst consensus on Apellis Pharmaceuticals is a Hold with an average price target of $39.59.

### Related Stocks

- [APLS.US](https://longbridge.com/en/quote/APLS.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [RY.US](https://longbridge.com/en/quote/RY.US.md)
- [RYTM.US](https://longbridge.com/en/quote/RYTM.US.md)
- [UTHR.US](https://longbridge.com/en/quote/UTHR.US.md)

## Related News & Research

- [Apellis Completes Biogen Merger and Goes Private](https://longbridge.com/en/news/286424730.md)
- [Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)](https://longbridge.com/en/news/286497683.md)
- [Leerink Partners Sticks to Their Buy Rating for Ibio (IBIO)](https://longbridge.com/en/news/286588262.md)
- [Eton Pharmaceuticals Q1 product sales rise driven by portfolio expansion](https://longbridge.com/en/news/286461579.md)
- [MiNK Therapeutics' Q1 net loss narrows slightly](https://longbridge.com/en/news/286558132.md)